NEWS

Patient enrollment has begun for a Phase II clinical trial for common warts.
For details, please refer to the following website.

Phase 2 clinical trial initiated for the treatment of cutaneous warts, a human papillomavirus infection.　
- Development of a novel antiviral drug against human papillomavirus -

An interview with our President Kuroishi was published in the LINK-J (Life Science Innovation Network Japan).

KinoPharma is pleased to announce that it has entered into a co-development and commercialization agreement with IWAKI SEIYAKU Co., Ltd. for the treatment of warts caused by human papillomavirus (HPV).

Our Kyoto Research Institute has been moved to the Kyoto University Katsura Venture Plaza, a research facility located adjacent to the Katsura Campus of Kyoto University.
We continue to promote R&D through close industry-academia collaboration.

KinoPharma is delighted to announce that the enrollment of subjects in the Phase I/II clinical trial for cervical dysplasia (CIN, a precursor to cervical cancer) has been completed.

KinoPharma is pleased to announce that it has decided to initiate the highest dose administration in a multiple-dose clinical trial in patients for cervical dysplasia (CIN, a precursor to cervical cancer) based on the recommendation of the Data Monitoring Committee.

Partnership with IWAKI SEIYAKU CO., LTD.

KinoPharma is delighted to announce that we have entered into a partnership with IWAKI SEIYAKU CO., LTD. for the development of drug formulations in the treatment of verruca and the supply of APIs. In conjunction with the partnership, IWAKI SEIYAKU has purchased new shares of the KinoPharma's stock through a private placement.

Along with its parent company IWAKI & CO., LTD., IWAKI SEIYAKU is engaged in the pharmaceutical and fine chemical businesses from research and development to manufacturing and sales of pharmaceuticals in order to contribute to human health and the pharmaceutical industry. In the pharmaceutical business, IWAKI SEIYAKU distinctively provides solutions in the field of dermatological diseases, through the global collaboration with pharmaceutical companies in the development and manufacture of topical products as well as through the manufacturing and sales of their dermatological product line.

KinoPharma is developing a new concept of antiviral drugs that target host factors to inhibit viral replication. The lead program is in Phase I/II for the treatment of cervical intraepithelial neoplasia (CIN) which is human papillomavirus (HPV) infection causing cervical cancer. KinoPharma is also developing therapeutic agents for various diseases caused by HPV infection, such as verruca vulgaris and condyloma acuminatum.

The partnership is expected to strengthen the supply system of APIs for antiviral drugs and accelerate the development of anti-HPV drugs in the field of dermatology, which will lead to further development and growth of KinoPharma.

KinoPharma is delighted to announce the enrollment of the first patient in a multiple-ascending-dose study in the Phase I/II clinical trial for cervical dysplasia (CIN, a precursor to cervical cancer).

KinoPharma is pleased to announce that it has decided to initiate a multiple-dose clinical trial in patients for cervical dysplasia (CIN, a precursor to cervical cancer), which has been ongoing since July of this year, based on the recommendation of the Data Monitoring Committee.

Kinopharma is delighted to announce the registration of the first subject in phase 1/2 clinical studies in Korea evaluating the safety and efficacy of the anti-HPV agent, Kinopharma’s flagship program, in patients with cervical intraepithelial neoplasia (CIN).

Cervical intraepithelial neoplasia (CIN) is human papillomavirus (HPV) infection of the cervix that could potentially lead to cervical cancer. Currently, there are no approved antiviral drugs for the treatment of CIN. Our clinical candidate anti-HPV agent is intended to treat CIN by removing any types of HPV from the cervix. We aim for the fastest approval of the anti-HPV agent.

Joint research on bovine papillomatosis with Obihiro University of Agriculture and Veterinary Medicine

Since last year, Kinopharma and Obihiro University of Agriculture and Veterinary Medicine (Associate Professor Tomas Acosta) have been engaged in joint research on bovine papillomatosis which is caused by Bovine Papillomavirus infection, using Kinopharma’s antiviral drug candidates. Based on the knowledge obtained last year, we have agreed to proceed with further joint research for verifying the effectiveness this year.
It is known that bovine papillomatosis is an infectious disease caused by bovine papilloma virus, and It has brought the problems of difficulty in milking and falling of dairy cow market price for the livestock industry. Bovine papillomavirus belongs to papillomaviridae similar to human papillomavirus, and Kinopharma has commenced the development of treatment for human papillomavirus infections such as cervical intraepithelial neoplasia (CIN) and common warts (viral warts).

At the Kyoto University Life Science Showcase held in San Diego, CEO Kuroishi made a presentation on our antiviral drug projects.

A clinical trial plan for cervical dysplasia was approved by the Korean Ministry of Food and Drug Safety (MFDS).

ASKA Pharmaceutical and KinoPharma Entered into Option Agreement for Treatment of Cervical Dysplasia.

Kyoto University started an investigator-initiated trial to treat cervical intraepithelial neoplasia, a precursor to cervical cancer, by administering a candidate anti-HPV drug provided by KinoPharma.

We launched a collaborative research project for exploring new drug development for alzheimer’s disease with National Institutes for Quantum and Radiological Science and Technology.

Our project "antiviral drug development for Human Papillomavirus(HPV), which causes cervical cancer", was adopted as a grant of the KYOTO Industrial Support Organization 21.

Mr. Kuroishi, CEO,showed the status of our business regarding development of the anti-virus agentat the "IPO Caravan" sponsored by the Mitsubishi UFJ Trust Bank.

Mr. Kuroishi, CEO, had an oral presentation at the "1st Healthcare Venture Conference KYOTO" held at the Kyoto Research Park.

We established the Exploratory Research Laboratory at the Innovation Hub Kyoto of Kyoto University.

NEDO Research Fund has been granted.